Targeting senescent cells in kidney disease, heart disease & diabetes

  • Research type

    Research Study

  • Full title

    Targeting senescent cells in kidney disease, heart disease & diabetes (TarSEC)

  • IRAS ID

    326318

  • Contact name

    Katie Mylonas

  • Contact email

    kmylonas@exseed.ed.ac.uk

  • Sponsor organisation

    University of Edinburgh

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    4 years, 9 months, 1 days

  • Research summary

    Some kidney cells become old or ‘senescent’ as a person gets older, or in disease. These cells produce harmful secretions causing kidney and heart scarring and preventing repair. Eliminating senescent cells increases healthy lifespan in mice. They are associated with chronic kidney disease (CKD), heart disease and diabetes. Higher numbers of senescent cells in kidney transplants reduce the length of time they function. Our research showed removing senescent kidney cells in mice using drugs before inducing kidney injury led to much less scarring and better kidney function.
    Special white blood cells in the body, called macrophages and natural killer cells, find and destroy senescent cells but this decreases as a person gets older and with disease. I will investigate how age and disease (CKD/heart disease/diabetes) reduces these cells ability to find and destroy senescent cells. Our aim is to develop better treatments for patients that help prevent build-up of these harmful cells in the organs that lead to organ scarring.
    This work will involve taking blood from patients with CKD, heart disease and diabetes. We will then extract the white blood cells from the blood to discover how disease affects the ability of these cells to find and eliminate the harmful senescent cells.

  • REC name

    HSC REC A

  • REC reference

    23/NI/0064

  • Date of REC Opinion

    10 May 2023

  • REC opinion

    Further Information Favourable Opinion